INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32701, 14498, 'Acetylsalicylic acid', 'Reye Syndrome', 'The use of salicylates, primarily aspirin, in children with varicella infections or influenza-like illnesses has been associated with an increased risk of Reye''s syndrome.  Although a causal relationship has not been established, the majority of evidence to date seems to support the association.  Most authorities, including the American Academy of Pediatrics Committee on Infectious Diseases, recommend avoiding the use of salicylates in children and teenagers with known or suspected varicella or influenza and during presumed outbreaks of influenza.  If antipyretic or analgesic therapy is indicated under these circumstances, acetaminophen may be an appropriate alternative.  The same precautions should also be observed with related agents such as salicylamide or diflunisal because of their structural and pharmacological similarities to salicylate.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32702, 26212, 'Acetylsalicylic acid', 'Reye Syndrome', 'The use of salicylates, primarily aspirin, in children with varicella infections or influenza-like illnesses has been associated with an increased risk of Reye''s syndrome.  Although a causal relationship has not been established, the majority of evidence to date seems to support the association.  Most authorities, including the American Academy of Pediatrics Committee on Infectious Diseases, recommend avoiding the use of salicylates in children and teenagers with known or suspected varicella or influenza and during presumed outbreaks of influenza.  If antipyretic or analgesic therapy is indicated under these circumstances, acetaminophen may be an appropriate alternative.  The same precautions should also be observed with related agents such as salicylamide or diflunisal because of their structural and pharmacological similarities to salicylate.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32703, 222, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32704, 1025, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32705, 1027, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32706, 1028, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32707, 1030, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32708, 2075, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32709, 4575, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32710, 4576, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32711, 9922, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32712, 9923, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32713, 9924, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32714, 12983, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32715, 13018, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32716, 13383, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32717, 14472, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32718, 14484, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32719, 14485, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32720, 14490, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32721, 14492, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32722, 14493, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32723, 14494, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32724, 14498, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32725, 26212, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32726, 222, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32727, 1025, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32728, 1027, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32729, 1028, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32730, 1030, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32731, 2075, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32732, 4575, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32733, 4576, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32734, 9922, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32735, 9923, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32736, 9924, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32737, 12983, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32738, 13018, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32739, 13383, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32740, 14472, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32741, 14484, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32742, 14485, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32743, 14490, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32744, 14492, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32745, 14493, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32746, 14494, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32747, 14498, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32748, 26212, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32749, 222, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32750, 1025, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32751, 1027, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32752, 1028, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32753, 1030, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32754, 2075, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32755, 4575, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32756, 4576, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32757, 9922, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32758, 9923, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32759, 9924, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32760, 12983, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32761, 13018, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32762, 13383, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32763, 14472, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32764, 14484, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32765, 14485, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32766, 14490, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32767, 14492, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32768, 14493, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32769, 14494, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32770, 14498, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32771, 26212, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32772, 222, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32773, 1025, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32774, 1027, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32775, 1028, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32776, 1030, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32777, 2075, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32778, 4575, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32779, 4576, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32780, 9922, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32781, 9923, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32782, 9924, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32783, 12983, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32784, 13018, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32785, 13383, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32786, 14472, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32787, 14484, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32788, 14485, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32789, 14490, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32790, 14492, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32791, 14493, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32792, 14494, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32793, 14498, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32794, 26212, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32795, 0, 'Betrixaban', 'Hemorrhage', 'The use of betrixaban is contraindicated in patients with active pathological bleeding.  Care and close monitoring is recommended when using this agent in patients who are receiving neuraxial anesthesia or undergoing spinal puncture as epidural or spinal hematomas may occur.  Consider risk of using this agent when scheduling patients for spinal procedures.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32796, 0, 'Betrixaban', 'Liver Diseases', 'The use of betrixaban is not recommended in patients with hepatic impairment as these patients may have intrinsic coagulation abnormalities.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32797, 0, 'Betrixaban', 'Kidney Diseases', 'Patients with severe renal impairment (CrCl >= 15 to < 30 mL/min computed by Cockcroft-Gault using actual body weight) may have an increased risk of bleeding events.  It is recommended to reduce the betrixaban dose in patients with severe renal impairment.  Monitor patients closely and promptly evaluate any signs or symptoms of blood loss in these patients.  No dose adjustment is needed for mild or moderate renal impairment (CrCl > 30 mL/min, computed by Cockcroft-Gault using actual body weight).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32798, 0, 'Betrixaban', 'Antiphospholipid Syndrome', 'Direct acting oral anticoagulants including factor Xa inhibitors and some thrombin inhibitors as dabigatran, are not recommended for use in patients with antiphospholipid syndrome (APS).  Treatment with these drugs has been associated with increased rates of recurrent thrombotic events, especially in patients with triple positive APS.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32799, 0, 'Abaloparatide', 'Hyperparathyroidism', 'Patients known to have an underlying hypercalcemic disorder, such as primary hyperparathyroidism, should not be treated with parathyroid hormone and its analogs because of the risk of exacerbating hypercalcemia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32800, 0, 'Abaloparatide', 'Neoplasms', 'Parathyroid hormone and its analogs should not be used in patients who are at increased baseline risk for osteosarcoma.  These agents should only be used if the potential benefits are considered to outweigh the potential risks.  Monitor these patients according to clinical guidelines.  Patients with bone metastases or a history of skeletal malignancies should not be treated with these agents.', '3', '', 'DDInter', 0);
